CA2125888A1 - Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty - Google Patents

Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty

Info

Publication number
CA2125888A1
CA2125888A1 CA002125888A CA2125888A CA2125888A1 CA 2125888 A1 CA2125888 A1 CA 2125888A1 CA 002125888 A CA002125888 A CA 002125888A CA 2125888 A CA2125888 A CA 2125888A CA 2125888 A1 CA2125888 A1 CA 2125888A1
Authority
CA
Canada
Prior art keywords
prevent
pharmaceutically active
containing composition
restenosis following
following angioplasty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002125888A
Other languages
French (fr)
Other versions
CA2125888C (en
Inventor
Harry B. Demopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Maintenance Programs Inc
Original Assignee
Harry B. Demopoulos
Health Maintenance Programs, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harry B. Demopoulos, Health Maintenance Programs, Inc. filed Critical Harry B. Demopoulos
Publication of CA2125888A1 publication Critical patent/CA2125888A1/en
Application granted granted Critical
Publication of CA2125888C publication Critical patent/CA2125888C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to formulations and methods for preventing and treating restenosis following angioplasty. This is accomplished by the regimented administration of a composition which includes selected antioxidants.
CA002125888A 1992-01-06 1993-01-04 Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty Expired - Fee Related CA2125888C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81729392A 1992-01-06 1992-01-06
US07/817,293 1992-01-06
PCT/US1993/000116 WO1993013660A1 (en) 1992-01-06 1993-01-04 Pharmaceutically active antioxydant containing composition and the method of its use to prevent and treat restenosis following angioplasty

Publications (2)

Publication Number Publication Date
CA2125888A1 true CA2125888A1 (en) 1993-07-22
CA2125888C CA2125888C (en) 2002-08-27

Family

ID=25222752

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002125888A Expired - Fee Related CA2125888C (en) 1992-01-06 1993-01-04 Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty

Country Status (5)

Country Link
US (1) US5326757A (en)
EP (1) EP0746202A4 (en)
JP (1) JPH07503010A (en)
CA (1) CA2125888C (en)
WO (1) WO1993013660A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU660630B2 (en) * 1990-10-01 1995-07-06 Brigham And Women's Hospital Beta-carotene and vitamin E therapy for inhibition of major vascular events
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5981568A (en) * 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6663881B2 (en) * 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
GB9314621D0 (en) * 1993-07-14 1993-08-25 Kodak Ltd Material supply
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
SE9500897D0 (en) * 1995-03-14 1995-03-14 Astra Ab The pharmacological use of certain cysteine derivatives
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide
US7611533B2 (en) 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
TW565558B (en) 1995-11-09 2003-12-11 Chugai Pharmaceutical Co Ltd Intimal thickening inhibitory agent
US6069167A (en) * 1996-01-16 2000-05-30 University Technology Corporation Use of antioxidant agents to treat cholestatic liver disease
US6113935A (en) * 1996-12-31 2000-09-05 Zeneca Limited Water-in-oil microencapsulation process and microcapsules produced thereby
JP2001507696A (en) * 1996-12-31 2001-06-12 アンチオキシダント ファーマシューティカルズ コーポレーション Pharmaceutical formulation of glutathione and method of administration thereof
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
US6201028B1 (en) 1998-12-08 2001-03-13 The Rockefeller University Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs
US6346547B1 (en) 1999-02-08 2002-02-12 Checkpoint, Genetics, Inc. N-substituted amino acids, antioxidant pharmaceutical compositions containing n-substituted amino acids and methods for preventing cardiovascular diseases and/or preventing and/or treating antioxidant responsive diseases therewith
DK1169322T3 (en) 1999-03-08 2006-03-06 Medicure Inc Pyridoxal analogues for the treatment of disorders caused by vitamin B6 deficiency
AU5840200A (en) * 1999-07-13 2001-01-30 Medicure Inc. Treatment of diabetes and related pathologies
JP2003507418A (en) * 1999-08-24 2003-02-25 メディキュア インターナショナル インコーポレイテッド Treatment of cardiovascular disease and related diseases
WO2001056572A1 (en) * 2000-02-02 2001-08-09 Metagenics, Inc. Compositions and methods for promoting healthy joints
JP2003525303A (en) 2000-02-29 2003-08-26 メディキュア インターナショナル インコーポレイテッド Cardioprotective phosphonates and malonates
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
JP2003528146A (en) 2000-03-28 2003-09-24 メディキュア インターナショナル インコーポレイテッド Treatment of cerebrovascular disease
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
WO2002004421A2 (en) 2000-07-07 2002-01-17 Medicure International Inc. Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US7375133B2 (en) 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
KR20050069975A (en) * 2002-07-29 2005-07-05 하와이 바이오테크, 인코포레이티드 Structural carotenoid analogs for the inhibition and amelioration of disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
CN1485072A (en) * 2002-09-28 2004-03-31 Coix seed oil soft capsule for curing prostate diseases and the application thereof
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
US9492493B2 (en) * 2003-09-22 2016-11-15 Dapeng Li Softgel of NLKJ for treating prostate diseases
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
CA2564066A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
AU2005259735A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
WO2006050598A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
JP2009517411A (en) * 2005-11-28 2009-04-30 メディキュア インターナショナル インコーポレーテッド Formulations for the treatment of cardiovascular and related medical conditions
US20080139668A1 (en) * 2006-12-12 2008-06-12 Korea Research Institute Of Bioscience And Biotechnology Pharmaceutical composition for obovatol for the prevention and treatment of restenosis
US20160367620A1 (en) * 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
MA51056A (en) * 2017-12-07 2020-10-14 Reven Ip Holdco Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454125A (en) * 1982-04-22 1984-06-12 Demopoulos Harry B Dry powder formulations having improved flow and compressibility characteristics, and method for the preparation thereof
EP0125252A1 (en) * 1982-11-16 1984-11-21 MOTSCHAN, Georges New utilization of a unique vitamin or a combination of various vitamins
DE3542309A1 (en) * 1985-11-29 1987-06-04 Cardona Federico Dr Medicinal antioxidant
FR2610626B1 (en) * 1987-02-09 1989-05-19 Oreal NOVEL ANTI-OXIDIZER SYSTEM BASED ON A STABILIZED ASCORBYL ESTER, COMPRISING AT LEAST ONE COMPLEXING AGENT AND AT LEAST ONE THIOL, AND COMPOSITIONS CONTAINING SUCH ANTI-OXIDIZING SYSTEM
WO1991002535A1 (en) * 1989-08-11 1991-03-07 Basil, Inc. Cancer prevention composition and method
JPH06192104A (en) * 1992-09-14 1994-07-12 Vesta Medicines Pty Ltd Composition for curing and preventing infantile dysbolism

Also Published As

Publication number Publication date
EP0746202A4 (en) 1997-06-25
US5326757A (en) 1994-07-05
WO1993013660A1 (en) 1993-07-22
JPH07503010A (en) 1995-03-30
CA2125888C (en) 2002-08-27
EP0746202A1 (en) 1996-12-11

Similar Documents

Publication Publication Date Title
CA2125888A1 (en) Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
EP0222483A3 (en) Use of gamma-linolenic acid and related compounds in the treatment of endometriosis
IE790756L (en) Cerebral therapeutic agent
IL111365A0 (en) (r)-5-carbamoyl -8-fluoro-3-n, n-disubstituted-amino-3, 4-dihydro-2h-1- benzopyrans
HUT72317A (en) Use of venflaxine or 3-aryloxi-propaneamine derivatives for preparing pharmaceutical compositions for treatment of incontinence
EP0943328A3 (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
AU4740893A (en) Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
AU7263591A (en) Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors
CA2173147A1 (en) Anti-obesity agent
AU2713992A (en) Therapeutic agent
CA2135709A1 (en) Melatonin derivatives for use in treating sleep disorders
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
TW325997B (en) Pharmaceutical composition for preventing and treating retinal diseases
CA2135710A1 (en) Melatonin derivatives for use in treating desynchronization disorders
CA2192822A1 (en) Use of immunosuppressive agents for the treatment of schizophrenia
UA74388C2 (en) Pharmaceutical compositions of tysoxanide and nitasoxanide
EP0618812A4 (en) Use of protease nexin-i as an antiinflammatory.
LT96094A (en) The active ingredient of pharmaceutical composition for treating constipation
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
IL98394A0 (en) Ws7622a mono or di-sulfate,salts thereof,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2188871A1 (en) Method for Treating Psoriasis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed